MAY 0 8 2002

			0 0 2	002
I hereby certify that this corre	spondence is being deposited	CERTIFICATE OF MAILING with the United States Postal Service	as first class mail in an envelope addressed to: Assista	00/2900
Commissioner for Patents, Wa Typed or Printed Name	Cindy Hoang		, #	=
Signature	Cros	Group	Date 4/23/02	5/
AMENDMENT UNDER 37 C.F.R. §1.111 Address to: Assistant Commissioner for Patents Washington, D.C. 20231		Attorney Docket	UCSF085CIP	
		Confirmation No. First Named Inventor	7019 NADEL	17
		Application Number	09/616,223	Wir
		Filing Date	July 14, 2000	1 1 7
		Group Art Unit	1635	711
		Examiner Name	J. Zara	
		Title	PREVENTING AIRWAY MUCUS PRODUCTION BY ADMINISTRATION OF EGF-R	

Sir:

This amendment is responsive to the Office Action dated January 2, 2002, for which a three-month period for response was given making this response due on or before April 2, 2002. A Petition for a one-Month Extension of Time is submitted herewith, making this amendment due on or before May 2, 2002. Accordingly, this response is timely filed.

In view of the remarks put forth below, reconsideration and allowance are respectfully requested.

I. AMENDMENTS

COPY OF PAPERS ORIGINALLY FILED

ANTAGONISTS

IN THE CLAIMS

Please enter the amendments to claims 1, 17, and 26, as shown below.

1. (Amended) A method of reducing goblet cell hyperplasia in an airway of an individual, comprising:

administering an epidermal growth factor receptor (EGF-R) antagonist that binds the EGF-R to a patient suffering from airway hypersecretion of mucus due to airway goblet cell hyperplasia in an amount effective to reduce goblet cell hyperplasia.

05/06/2002 NMOHAMM1 00000022 500815 0961688

01 FC:115 110.00 S

17. (Amended) A pharmaceutical formulation for reducing goblet cell hyperplasia in an

airway, comprising:

a therapeutically effective amount of an epidermal growth factor receptor (EGF-R)

antagonist that binds an EGF-R in a dose sufficient to reduce goblet cell hyperplasia in an airway;